Thiazide Diuretics in Chronic Kidney Disease

Guideline Recommendations

• The American Journal of Kidney Diseases recommends thiazide diuretics as first-line agents for hypertension treatment across all CKD stages, alongside ACE inhibitors, ARBs, and calcium channel blockers 1, 2
• The KDOQI work group explicitly disagreed with older statements suggesting thiazides should not be used in advanced CKD due to lack of efficacy 1

Evidence of Efficacy in Advanced CKD

• Chlorthalidone 25 mg reduced 24-hour ambulatory blood pressure by 10.5 ± 3.1 mm Hg in patients with mean eGFR of 26.8 mL/min/1.73 m² over 12 weeks 1, 3
• Chlorthalidone is the preferred thiazide in CKD patients due to longer half-life and superior efficacy demonstrated in major blood pressure trials 1, 3, 6

Clinical Algorithm for Use in CKD

• The American Journal of Kidney Diseases suggests using thiazides as first-line agents without hesitation in Stage 1-3 CKD (eGFR ≥30 mL/min/1.73 m²) 1, 2
• Chlorthalidone 12.5-25 mg daily is preferred over hydrochlorothiazide in Stage 1-3 CKD 3, 6
• Consider chlorthalidone 25 mg daily for resistant hypertension in Stage 4-5 CKD (eGFR <30 mL/min/1.73 m²) 1, 3

Monitoring Requirements

• Check electrolytes (sodium, potassium) and renal function within 2-4 weeks of initiation 3
• Elderly patients have heightened risk of hyponatremia requiring closer surveillance 1, 3

Common Pitfalls to Avoid

• Avoid potassium-sparing diuretics (amiloride, triamterene) when GFR <45 mL/min due to hyperkalemia risk 4, 5, 3
• Monitor closely when combining thiazides with ACE inhibitors or ARBs for hyperkalemia and acute kidney injury 1, 3
• Never combine ACE inhibitors with ARBs, regardless of diuretic use 1, 2